Enhertu secures positive EU panel backing for first pan-tumor HER2 therapy
Share
Enhertu (trastuzumab deruxtecan) moved a step closer to a milestone regulatory approval in Europe, securing a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) as a tumor-agnostic treatment for advanced solid malignancies.
